The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.
A bench comprising Chief Justice Ranjan Gogoi and Justice Deepak Gupta held the former Ranbaxy promoters guilty of contempt of court and said that they had violated its earlier order by which the sale of their controlling stakes in Fortis Group to Malayasian firm IHH Healthcare was put on hold.
One Chinese source informed ANI that 10 million new infections are probably occurring daily in China.
The company claimed that the AYUSH ministry has "categorically agreed" that Patanjali had "appropriately worked on COVID-19 management".
The government is hopeful of a speedy launch of single-dose COVID-19 vaccine Sputnik Light in India and all stakeholders, including the Russian manufacturer and its Indian partners, have been directed to fast-track the application and regulatory approval procedures for the jab to boost the country's vaccination drive, sources said.
Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV). The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the country's first and only Phase III efficacy study for a COVID-19 vaccine, a press release from the vaccine maker said on Saturday night.
The resultant price increase was the cause of a surprise upward variation in the "drug and medicines" segment of the weekly wholesale price index of the ministry of commerce and Industry last week, it is learnt.
Cipla is among the three Indian companies that signed a non-exclusive licensing agreement with US-based Gilead Sciences to make and distribute the latter's repurposed Ebola drug Remdesivir in 127 countries including India.
India is currently using two vaccines for COVID-19 -- one developed by Oxford University and AstraZeneca and the other developed by Bharat Biotech in collaboration with the Indian Council of Medical Research-National Institute of Virology. Both the vaccines are being manufactured within the country by domestic firms.
Risk is difficult to evaluate, warns Harsh Roongta.
Alembic Ltd would be acquiring brand and trademark rights for 'Yutopar' drug from Dutch pharma entity Solvay Pharmaceuticals BV for an undisclosed amount, subject to regulatory approvals.
Stiff competition in a highly fragmented market has led the domestic drug makers to depend on brand extensions rather than new product launches to corner a market share. A market intelligence study, organised by prescription audit company ORG IMS Health, has found that one in every three brands launched in the country is a brand extension. Such products comprise 18 per cent of the Rs 28,000-crore domestic pharmaceutical market.
Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India seeking emergency use authorisation for their COVID-19 vaccines.
Under MRA, Japan is to recognise Indian medical degrees and treat the country's doctors and other medical personnel on par with its own.
The woman is a first-year PhD student and she has alleged that Anmol Ratan, a JNU student and AISA activist raped her on Saturday, police said.
Netmeds is looking at using new technologies such as deep learning and data analytics to improve forecasting in terms of the demand of the products for pharma companies, reports Peerzada Abrar.
An expert panel of India's Central Drug Authority on Tuesday recommended granting permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years with certain conditions, official sources said.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.
Pharma companies gear up for the 'new normal' as they train and align their sales forces for a paradigm shift. GSK leads the charge with staggered return-to-work, others plans yoga sessions and health care webinars for salesperson's family.
While Ramdev claimed that Ayurved-based 'Coronil and Swasari' medicine have shown 100 per cent favourable results during clinical trials on COVID-19 infected patients except those on a life support system, the Ayush Ministry sought from the company detailed report on composition, testing and other data of the drugs.
The global heath body had earlier suspended the hydroxychloroquine arm of the clinical trials of experimental COVID-19 drugs over safety concerns.
On Tuesday, Rao said there was a possibility of the PM's visit to Pune, and if that happens, it would be aimed at reviewing the status of the vaccine candidate for coronavirus infection and to know about its launch, production and distribution mechanisms.
Aurobindo Pharma has acquired business assets of the UK-based generic drug maker Milpharm.
As the controversy over Bishop Joseph Kallarangatt's remarks refused to die down, the chief minister said the Kerala society as a whole has not agreed with the Bishop's statement and expressed hope that he would "respond", sensing the stand of the public on the issue.
"We are looking at targets with a bottom line of Rs 50-60 crore (Rs 500-600 million) to expand our CRAMS business in various markets," said Ashok Shinkar, director, Wanbury. The company plans to increase its turnover to over Rs 900 crore (Rs 9 billion) within the next three years.
The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS in New Delhi on Thursday, with Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.
MoUs range across pharma, telecom, IT and homeland security.
It, however, was a record-smashing week for both the indices, which scaled their lifetime highs.
In November, DRL registered growth of 28 per cent year-on-year (YoY), which was the highest among peers and double that of the industry growth (14.5 per cent).
The expert committee sought more information from Serum Institute regarding the Oxford-AstraZeneca vaccine.
An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
With 40 million diabetic patients and an equal number of people estimated to be diabetic prone, India is emerging as a major market for blood glucose monitoring solutions.
India is currently under the 21-day lockdown since March 25, with only essential services exempted to contain the fast-spreading virus.
The S&P BSE Sensex ended the session at 25,342, up 3 points while the Nifty50 closed at 7,738 points.
The west is faced with a daunting task on patent expiry, increasing challenges from generics, pipeline showing limited blockbusters, and in addition to that increasing pricing pressure.
The domestic pharmaceuticals industry has proven its mettle once again with Glenmark Pharmaceuticals announcing the receipt of euro 25 million from German drug major Merck
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances